VXRT News and Press, Vaxart Inc. From 08/05/22

A proposal to increase the number of Vaxart ( NASDAQ: VXRT ) authorized shares to 250M has been approved by shareholders . The proposal won the backing of 82% of the voting shares at a Thursday meeting. Vaxart ( VXRT ) adjourned a June shareholder meeting in or...

All six proposals approved in the 2022 Proxy Statement Vote strengthens the Company as it progresses its oral vaccine programs SOUTH SAN FRANCISCO, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) announced today that at its reconvened Annual Meet...

Vaxart (NASDAQ: VXRT) might just be gearing up to steal coronavirus vaccine market share from Moderna (NASDAQ: MRNA) in the next couple of years, making its investors wealthy in the process. The biotech's vaccine tablets could have a few advantages that Moderna's shots don't...

Check out Seeking Alpha's full interview with Vaxart executives James Cummings and Sean Tucker in the above video . Going to get a vaccine is rarely a painless experience, but Vaxart ( NASDAQ: VXRT ) is aiming to change that as the biotech is focused exclusively on devel...

In advance of an August 4 shareholder meeting, Vaxart ( NASDAQ: VXRT ) is again encouraging its shareholders to vote for a proposa l that would increase the number of its shares to 250M. The biotech, which is focused on developing pill vaccines, said that more than 80%...

SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2022 after the market close on Monday, August 8, 2022. The Vaxart senior manag...

Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today urg...

A recent study found that Vaxart's ( NASDAQ: VXRT ) oral COVID-19 vaccine produced antibodies in the body's mucosal tissues in the nose and lungs as opposed to the bloodstream with currently authorized COVID vaccines. The phase 1 study was conducted by the company and has ...

Vaxart ( NASDAQ: VXRT ) on Wednesday reported additional phase 1 data showing that its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against COVID-19, and all tested coronaviruses. This additional data supports i...

Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data gained from trial as it develops additional vaccine candidates SOUTH SAN FRANCISCO, Calif., July 20, ...